Most women diagnosed with cervical cancer are those who screens irregularly or have never been screened for it. Human Papillomavirus (HPV) is the main cause of cervical cancer. It is known to cause cell changes in the cervix and may lead to the development of cervical cancer.
How to prevent cervical cancer:
Cervical cancer can be prevented by undergoing regular screening through co-testing of Liquid Based-Cytology (LBC) and HPV DNA Genotyping Test.
The Advantages of Combined LBC + HPV DNA Test:
• Better detection
Co-testing increased the detection of cervical cancer
• Better management
If tested positive for HPV but LBC indicates no cell changes, condition can be closely monitored.
• Cost effective
Co-testing using the combination of cytology plus HPV DNA testing is the appropriate screening for women >30 years old. If tested negative for both tests, the screening interval is no sooner than 3 years
subsequently. (NCCN Guidelines Version 1.2011 Cervical Cancer Screening)
In the event of cancer, a lot of genes was found to be highly methylated. This occurrence is found in the majority of cervical pre-cancerous or cancerous lesions but not in the normal or benign lesions. Therefore, methylated gene can be used to distinguish patients at minimal or high-risk of progressing to cancer.
MethylCheck - The Leading Molecular Marker for Cervical Cancer
Abnormal DNA methylation has been identified as a signature event of carcinogenesis. As a result, DNA methylation can serve as bio-markers for early detection of cancers. PAX1 gene was found to be highly methylated in the majority of cervical pre-cancerous or cancerous lesions but not in the normal or benign lesions. MethylCheck detects the methylated PAX1 gene in genomic DNA extracted from cervical cells.
• Women with Pap result showed ASCUS (Atypical Squamous Cells of Undetermined Significance)
• Women with persistent High-risk HPV infection
Find out more about other tests in this category:
• Ovarian Cancer Screening
• Breast Cancer Screening